Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Parnia Stem Cell Institute is a biotechnology company based in Iran that specializes in regenerative medicine and advanced cell therapies. The institute focuses on the isolation, expansion, and clinical application of mesenchymal stem cells (MSCs), fibroblasts, and melanocytes for treating a variety of degenerative and chronic conditions. Their product portfolio includes cell-based treatments for orthopedic disorders like osteoarthritis and dermatological applications such as skin rejuvenation and vitiligo treatment. Parnia operates as a bridge between laboratory research and clinical practice, providing standardized cell products and cell banking services to healthcare providers. The company maintains a strong focus on GMP-compliant manufacturing to ensure the safety and efficacy of its autologous and allogeneic cell products.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Parnia Stem Cell Institute.